Related Experiment Videos
The utilization of trifluorothymidine (TFT) to select for thymidine kinase-deficient (TK-/-) mutants from
Abstract:
Trifluorothymidine (TFT), a thymidine analog, was analyzed for its ability to select for thymidine kinase-deficient (TK-/-) mutants. In comparison with BUdR, the traditional selective agent for TK-/- cells, it was determined that TFT at 1/50th the dose (1 microgram/ml vs. 50 microgram/ml) is a more effective and versatile selective agent for TK-/- mutants arising from the TK+/- -3.7.2C heterozygote of L5178Y mouse lymphoma cells. Since TFT acts more rapidly than BUdR, it can be utilized in procedures (such as the analysis of the phenotypic lag) requiring the fast arrest of cell division. Reconstruction analyses of effective TK-/- mutant recovery indicate that TFT can be used to recover mutants from significantly higher densities of TK+/- cells than can BUdR. In addition, TK-/- mutants can attain larger colony size in TFT than in BudR where severe stunting of growth occurs at high TK-/- cell densities. 190 of 194 isolated TFT-resistant large and small colony mutants (both spontaneous and induced).
Insights
Trifluorothymidine (TFT) is a more effective agent for selecting thymidine kinase-deficient (TK-/-) mutants than BUdR. TFT works faster and allows for mutant recovery from higher cell densities, improving TK-/- mutant selection in mouse lymphoma cells.
Area of Science:
- Biochemistry
- Cell Biology
- Genetics
Background:
- Thymidine kinase (TK) is crucial for DNA synthesis and repair.
- TK-deficient (TK-/-) cells are resistant to certain nucleoside analogs.
- Selective agents are needed to isolate TK-/- mutants for genetic studies.
Purpose of the Study:
- To evaluate Trifluorothymidine (TFT) as a selective agent for TK-/- mutants.
- To compare the efficacy of TFT with the traditional agent, BUdR.
- To assess TFT's utility in various cell culture conditions and procedures.
Main Methods:
- L5178Y mouse lymphoma cells (TK+/- -3.7.2C heterozygote) were used.
- Trifluorothymidine (TFT) and Bromodeoxyuridine (BUdR) were employed as selective agents.
- Mutant recovery, cell density tolerance, and colony growth were analyzed.
Main Results:
- TFT is significantly more effective than BUdR at a 50-fold lower dose (1 µg/ml vs. 50 µg/ml).
- TFT allows for mutant recovery from higher TK+/- cell densities compared to BUdR.
- TK-/- mutants exhibit larger colony sizes in TFT, whereas BUdR causes growth stunting at high cell densities.
- TFT's rapid action facilitates cell division arrest for procedures like phenotypic lag analysis.
Conclusions:
- Trifluorothymidine (TFT) is a superior selective agent for isolating thymidine kinase-deficient (TK-/-) mutants.
- TFT offers advantages in speed, efficiency, and versatility over BUdR for TK-/- mutant selection.
- TFT enhances the recovery and analysis of TK-/- mutants in mouse lymphoma cell lines.